
Novo Nordisk cuts price of Ozempic; NIH gene-editing advance offers hope for Tay-Sachs; bee-stinger microneedles speed healing, track wounds – Morning Medical Update
Key Takeaways
- Novo Nordisk's price reduction for Ozempic targets uninsured patients, offering home delivery and access through multiple platforms to improve affordability and adherence to FDA-approved treatments.
- NIH's gene-editing research for Tay-Sachs disease shows potential in increasing enzyme activity, easing symptoms, and extending lifespan in mice, offering hope for future therapies.
The top news stories in medicine today.
Scientists in China have designed a microneedle patch inspired by honeybee stingers that can lock into the skin, release insulin, stimulate healing and monitor wounds in real time. The smart dressing, detailed in the
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.















